Veracyte Inc (FRA:12V)
€ 30.2 -0.2 (-0.66%) Market Cap: 2.33 Bil Enterprise Value: 2.14 Bil PE Ratio: 0 PB Ratio: 2.28 GF Score: 84/100

Veracyte Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 09, 2020 / 05:25PM GMT
Release Date Price: €26 (-2.26%)
Catherine Walden Ramsey Schulte
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

All right. Hello, everyone. Thank you for joining us today. I'm Catherine Schulte. I cover life sciences and diagnostics here at Baird. We're very excited to have Veracyte here presenting at our conference today. Veracyte is a global diagnostics company that uses genomic information to improve diagnosis and treatment decisions for patients with thyroid cancer, lung cancer and IPF. So here representing the company, we have the CEO, Bonnie Anderson. So thank you so much, Bonnie, for being here with us.

Bonnie H. Anderson
Veracyte, Inc. - Co-Founder, Chairman & CEO

Catherine, thank you so much for the great introduction and thank you for the invitation to be part of Baird's Global Health Care Conference this year. I'm very excited for that. I just want to remind everyone briefly of the forward-looking statements that we'll make before we begin. And walk you through the Veracyte story, which has changed quite a bit over the course of the last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot